Comparison Tool

Select a country from the regions above then, add your country to our comparison tool to compare country specific information simultaneously across 3 countries


Fast Facts

  • Capital: Mexico City
  • Economy: 13th largest in the world. Nominal GDP US$ 1.231 trillion, 2012
  • Health Expenditure: 3% of GDP, 2008
  • Population: 115 million, 2011
  • Average Life Span: 77 years, 2011
  • Languages: Spanish, and indigenous languages
  • Adult Literacy Rate: 93.4%, 2009

Health Trends

  • Centralised healthcare systems
  • Obesity in Mexican adults has shown a remarkable increase over time. Data from 1993 revealed an obesity prevalence of 21.5% in adults, which rose to 24% in 2000, and further to 30% in adults in 2006.  Obesity also increases the risk of chronic illnesses such as diabetes, cardiovascular disease and some cancers
  • Nearly half of Mexico’s inhabitants have no health insurance benefits
  • Every medium-large city has a first rate hospital
  • Health care is half of what you expect to pay in the U.S.
  • Medicines are widely available and prices are much lower than in the U.S.
  • Prescription drugs cost on average about 50% less to manufacture than in the U.S
  • Health care is divided into three divisions: social security, government services, and private sector health care

Clinical Trial Landscape

  • Ranks among the top 10 pharmaceutical markets in the world; largest in Latin America
  • Total number of clinical trials – 1,023, Sept. 2009
  • More than 70% of clinical trials are conducted in government-backed hospitals and public institutions
  • Major therapeutic areas: Metabolics (especially Type 2 Diabetes & Metabolic Syndrome), Cardiovascular (Hypertension), Rheumatology, Infectious Diseases, Respiratory, CNS, Oncology
  • Great location for the conduct of paediatric trials, approximately 43 million aged 19 yrs or less Market is dominated by foreign companies; few domestic players
  • Nearly all major multinational pharma companies are present, including Abbott, AZ, BMS, Merck, GSK, Lilly, Novartis, Pfizer, Sanofi, Schering and others
  • Western trained investigators
  • Large treatment-naïve populations, high patient retention rates, strong physician-patient relationships
  • Centralised healthcare systems
  • Well established regulatory process based on ICH GCP
  • Average approval time: 14-18 weeks
  • To date, five national regulatory authorities have been recognized by PAHO/WHO as National Regulatory Authorities of Regional Reference, among these the Federal Commission for Protection against Sanitary Risks of the United Mexican States (COFEPRlS)

ICON in Mexico

Add to Comparison Tool
  • Established in 2004
  • 209 Employees, 2017
  • Total awarded studies: 156 (2004-YTD 2012), and currently participating in 36 studies in various therapeutic areas including Diabetes, Cardiovascular, CNS, Oncology, HIV, Rheumatoid Arthritis, Psoriasis and Transplants
  • Majority of studies in Oncology, Cardiovascular, Metabolics and CNS
  • Active participation in CRO Association in Mexico (ACROM)

Services Offered

  • Clinical Trial Management and Clinical Operations (Phase II - III)
  • Safety Study start-up and Feasibility
  • Clinical Monitoring
  • Medical & Safety Services
  • Late Phase Research (Ph IV)
  • Coverage of other countries (recent examples including Guatemala and Puerto Rico)
  • Quality Assurance
  • DOCS Resourcing Solutions: 
    • Functional Resourcing 
    • Flexible Resourcing
    • Permanent Recruitment 

Contact Us for further information